Therapeutic potential of the neutralizing monoclonal antibody 45G3 against encephalomyocarditis virus
Abstract Encephalomyocarditis virus (EMCV), a potential zoonotic pathogen, poses significant socioeconomic and public health challenges across various host species. Although EMCV rarely triggers severe clinical symptoms in humans, its widespread prevalence and unique biological characteristics under...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Animal Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s44149-024-00154-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832585923622076416 |
|---|---|
| author | Yanfang Zhang Zhiying Wang Yaohui Fang Qiong Zhu Jie Fu Sijing Hu Jiayin Jin Min Zhou Xijia Liu Danna Zhang Shouwei Huang Yali Deng Lingling Xie Shu Shen Jing Ye Fei Deng Shengbo Cao |
| author_facet | Yanfang Zhang Zhiying Wang Yaohui Fang Qiong Zhu Jie Fu Sijing Hu Jiayin Jin Min Zhou Xijia Liu Danna Zhang Shouwei Huang Yali Deng Lingling Xie Shu Shen Jing Ye Fei Deng Shengbo Cao |
| author_sort | Yanfang Zhang |
| collection | DOAJ |
| description | Abstract Encephalomyocarditis virus (EMCV), a potential zoonotic pathogen, poses significant socioeconomic and public health challenges across various host species. Although EMCV rarely triggers severe clinical symptoms in humans, its widespread prevalence and unique biological characteristics underscore the need for continuous surveillance and the development of effective therapeutics and prophylactics. In this study, we evaluated the neutralizing effects of a monoclonal antibody derived from the spleens of mice immunized with EMCV virus-like particles (VLPs), both in vitro and in vivo. Using recombinant DNA technology, we engineered a baculovirus system to express EMCVs P12A and 3C, facilitating the production of VLPs in Sf9 cells. These VLPs serve as antigens to immunize mice, leading to the isolation of the monoclonal antibody 45G3. This antibody exhibited high specificity for EMCV conformational epitopes, excluding linear epitopes, and demonstrated potent in vitro neutralizing activity, with an IC50 of 0.01873 μg/mL. Immunoelectron microscopy (IEM) revealed a strong direct interaction between the 45G3 antibody and EMCV particles. Virus adsorption inhibition assays demonstrated that 45G3 effectively blocked viral attachment, thereby preventing further infection of host cells. These findings further support the notion of a robust interaction between the virus and the antibody. Moreover, in vivo assessments revealed that 45G3 significantly reduced viral loads in treated mice and improved survival outcomes following EMCV exposure. Additionally, posttreatment analysis revealed reduced tissue damage and a markedly decreased inflammatory response in the brain, indicating that the 45G3 antibody effectively blocked viral infection, thereby mitigating tissue damage and enhancing survival. These findings position 45G3 as a promising candidate for EMCV management and provide a strong foundation for the future development of antiviral drugs targeting this widespread virus. |
| format | Article |
| id | doaj-art-849227209d484c8c903a9a356fc9201a |
| institution | Kabale University |
| issn | 2731-0442 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Animal Diseases |
| spelling | doaj-art-849227209d484c8c903a9a356fc9201a2025-01-26T12:22:34ZengBMCAnimal Diseases2731-04422025-01-015111610.1186/s44149-024-00154-7Therapeutic potential of the neutralizing monoclonal antibody 45G3 against encephalomyocarditis virusYanfang Zhang0Zhiying Wang1Yaohui Fang2Qiong Zhu3Jie Fu4Sijing Hu5Jiayin Jin6Min Zhou7Xijia Liu8Danna Zhang9Shouwei Huang10Yali Deng11Lingling Xie12Shu Shen13Jing Ye14Fei Deng15Shengbo Cao16National Key Laboratory of Agricultural Microbiology, Huazhong Agricultural UniversityKey Laboratory of Virology and Biosafety and National Virus Resource Center, Wuhan Institute of Virology, Chinese Academy of SciencesKey Laboratory of Virology and Biosafety and National Virus Resource Center, Wuhan Institute of Virology, Chinese Academy of SciencesKey Laboratory of Virology and Biosafety and National Virus Resource Center, Wuhan Institute of Virology, Chinese Academy of SciencesKey Laboratory of Virology and Biosafety and National Virus Resource Center, Wuhan Institute of Virology, Chinese Academy of SciencesKey Laboratory of Virology and Biosafety and National Virus Resource Center, Wuhan Institute of Virology, Chinese Academy of SciencesKey Laboratory of Virology and Biosafety and National Virus Resource Center, Wuhan Institute of Virology, Chinese Academy of SciencesKey Laboratory of Virology and Biosafety and National Virus Resource Center, Wuhan Institute of Virology, Chinese Academy of SciencesKey Laboratory of Virology and Biosafety and National Virus Resource Center, Wuhan Institute of Virology, Chinese Academy of SciencesKey Laboratory of Virology and Biosafety and National Virus Resource Center, Wuhan Institute of Virology, Chinese Academy of SciencesKey Laboratory of Virology and Biosafety and National Virus Resource Center, Wuhan Institute of Virology, Chinese Academy of SciencesKey Laboratory of Virology and Biosafety and National Virus Resource Center, Wuhan Institute of Virology, Chinese Academy of SciencesKey Laboratory of Virology and Biosafety and National Virus Resource Center, Wuhan Institute of Virology, Chinese Academy of SciencesKey Laboratory of Virology and Biosafety and National Virus Resource Center, Wuhan Institute of Virology, Chinese Academy of SciencesNational Key Laboratory of Agricultural Microbiology, Huazhong Agricultural UniversityKey Laboratory of Virology and Biosafety and National Virus Resource Center, Wuhan Institute of Virology, Chinese Academy of SciencesNational Key Laboratory of Agricultural Microbiology, Huazhong Agricultural UniversityAbstract Encephalomyocarditis virus (EMCV), a potential zoonotic pathogen, poses significant socioeconomic and public health challenges across various host species. Although EMCV rarely triggers severe clinical symptoms in humans, its widespread prevalence and unique biological characteristics underscore the need for continuous surveillance and the development of effective therapeutics and prophylactics. In this study, we evaluated the neutralizing effects of a monoclonal antibody derived from the spleens of mice immunized with EMCV virus-like particles (VLPs), both in vitro and in vivo. Using recombinant DNA technology, we engineered a baculovirus system to express EMCVs P12A and 3C, facilitating the production of VLPs in Sf9 cells. These VLPs serve as antigens to immunize mice, leading to the isolation of the monoclonal antibody 45G3. This antibody exhibited high specificity for EMCV conformational epitopes, excluding linear epitopes, and demonstrated potent in vitro neutralizing activity, with an IC50 of 0.01873 μg/mL. Immunoelectron microscopy (IEM) revealed a strong direct interaction between the 45G3 antibody and EMCV particles. Virus adsorption inhibition assays demonstrated that 45G3 effectively blocked viral attachment, thereby preventing further infection of host cells. These findings further support the notion of a robust interaction between the virus and the antibody. Moreover, in vivo assessments revealed that 45G3 significantly reduced viral loads in treated mice and improved survival outcomes following EMCV exposure. Additionally, posttreatment analysis revealed reduced tissue damage and a markedly decreased inflammatory response in the brain, indicating that the 45G3 antibody effectively blocked viral infection, thereby mitigating tissue damage and enhancing survival. These findings position 45G3 as a promising candidate for EMCV management and provide a strong foundation for the future development of antiviral drugs targeting this widespread virus.https://doi.org/10.1186/s44149-024-00154-7Encephalomyocarditis virusMonoclonal antibodyVirus-like particlesNeutralizing activityTherapeutic efficacyAntiviral development |
| spellingShingle | Yanfang Zhang Zhiying Wang Yaohui Fang Qiong Zhu Jie Fu Sijing Hu Jiayin Jin Min Zhou Xijia Liu Danna Zhang Shouwei Huang Yali Deng Lingling Xie Shu Shen Jing Ye Fei Deng Shengbo Cao Therapeutic potential of the neutralizing monoclonal antibody 45G3 against encephalomyocarditis virus Animal Diseases Encephalomyocarditis virus Monoclonal antibody Virus-like particles Neutralizing activity Therapeutic efficacy Antiviral development |
| title | Therapeutic potential of the neutralizing monoclonal antibody 45G3 against encephalomyocarditis virus |
| title_full | Therapeutic potential of the neutralizing monoclonal antibody 45G3 against encephalomyocarditis virus |
| title_fullStr | Therapeutic potential of the neutralizing monoclonal antibody 45G3 against encephalomyocarditis virus |
| title_full_unstemmed | Therapeutic potential of the neutralizing monoclonal antibody 45G3 against encephalomyocarditis virus |
| title_short | Therapeutic potential of the neutralizing monoclonal antibody 45G3 against encephalomyocarditis virus |
| title_sort | therapeutic potential of the neutralizing monoclonal antibody 45g3 against encephalomyocarditis virus |
| topic | Encephalomyocarditis virus Monoclonal antibody Virus-like particles Neutralizing activity Therapeutic efficacy Antiviral development |
| url | https://doi.org/10.1186/s44149-024-00154-7 |
| work_keys_str_mv | AT yanfangzhang therapeuticpotentialoftheneutralizingmonoclonalantibody45g3againstencephalomyocarditisvirus AT zhiyingwang therapeuticpotentialoftheneutralizingmonoclonalantibody45g3againstencephalomyocarditisvirus AT yaohuifang therapeuticpotentialoftheneutralizingmonoclonalantibody45g3againstencephalomyocarditisvirus AT qiongzhu therapeuticpotentialoftheneutralizingmonoclonalantibody45g3againstencephalomyocarditisvirus AT jiefu therapeuticpotentialoftheneutralizingmonoclonalantibody45g3againstencephalomyocarditisvirus AT sijinghu therapeuticpotentialoftheneutralizingmonoclonalantibody45g3againstencephalomyocarditisvirus AT jiayinjin therapeuticpotentialoftheneutralizingmonoclonalantibody45g3againstencephalomyocarditisvirus AT minzhou therapeuticpotentialoftheneutralizingmonoclonalantibody45g3againstencephalomyocarditisvirus AT xijialiu therapeuticpotentialoftheneutralizingmonoclonalantibody45g3againstencephalomyocarditisvirus AT dannazhang therapeuticpotentialoftheneutralizingmonoclonalantibody45g3againstencephalomyocarditisvirus AT shouweihuang therapeuticpotentialoftheneutralizingmonoclonalantibody45g3againstencephalomyocarditisvirus AT yalideng therapeuticpotentialoftheneutralizingmonoclonalantibody45g3againstencephalomyocarditisvirus AT linglingxie therapeuticpotentialoftheneutralizingmonoclonalantibody45g3againstencephalomyocarditisvirus AT shushen therapeuticpotentialoftheneutralizingmonoclonalantibody45g3againstencephalomyocarditisvirus AT jingye therapeuticpotentialoftheneutralizingmonoclonalantibody45g3againstencephalomyocarditisvirus AT feideng therapeuticpotentialoftheneutralizingmonoclonalantibody45g3againstencephalomyocarditisvirus AT shengbocao therapeuticpotentialoftheneutralizingmonoclonalantibody45g3againstencephalomyocarditisvirus |